Clinical and Cost Implications of Newer Therapies within the Management of PAH: A Focus on Accurate, Timely, and Individualized Care

Clinical and Cost Implications of Newer Therapies within the Management of PAH: A Focus on Accurate, Timely, and Individualized Care

Live Webinar

H. Eric Cannon, PharmD, FAMCP
Chief of Pharmacy
Murray, Utah

Richard N. Channick, MD
Director, Pulmonary Hypertension and Thromboendarterectomy Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts 

Intended Learners

The intended audience for this activity is pharmacy directors, medical directors, and other health plan decision makers whose patient population includes individuals infected with PAH.

Learning Objectives

After completing this actvity, participants should be able to:

  • Evaluate the clinical and economic consequences associated with suboptimal PAH management
  • Outline the latest clinical data regarding newer PAH agents and combination therapies
  • Implement diagnostic and treatment protocols for PAH that reflect guidelines and recent clinical evidence
  • Evaluate the impact of new PAH treatments and combination strategies on plan medical/pharmacy spend and benefit design
  • Translate clinical/cost data, current treatment guidelines, and individualized care strategies to formulary placement decisions and medical/pharmacy benefit design
Activity Overview

To be eligible for documentation of credit, participants must attend the live webinar, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation, participants may immediately print their documentation of credit.

There is no fee associated with this activity.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to


   In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


NACCME designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credit™from organizations accredited by the ACCME.


This activity is approved for 1.0 contact hour (.10 CEU) of continuing pharmacy education (UAN 0276-0000-17-109-L01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Peter Oettgen, MD, Associate Professor of Medicine, Harvard Medical School, Director of Preventive Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Planning Committee

The planning committee comprises H. Eric Cannon, PharmD, FAMCP, Robert N Channick, MD, Peter Oettgen, MD; and Donna Brophy, Mary Johnson, Randy Robbin, John Savage, and Margaret Stefan, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Cannon: Speaker-Abbvie, Consultant-Gilead

Dr. Channick: Consultant-Acetlion, Arena, Bayer; Research Grant-Actelion, Bayer

Dr. Oettgen has disclosed no relevant financial relationships with any commercial interest.

Ms. Brophy, Ms. Johnson, Mr. Robbin, Mr. Savage, and Ms. Stefan have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed no off label/unapproved uses of drugs and/or devices will be discussed in the presentations.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

Support provided by Bayer Healthcare Pharmaceuticals Inc.